메뉴 건너뛰기
Annals of the New York Academy of Sciences
Volumn 803, Issue , 1996, Pages 213-223
Camptothecin and its analogs: An overview of their potential in cancer therapeutics
Author keywords

[No Author keywords available]
Indexed keywords

9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC ALKALOID; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CYTOKINE; IRINOTECAN; TOPOTECAN;
EID: 0030482362     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26391.x     Document Type: Conference Paper
Times cited : (35)
References (71)
  • 2
    • 0015378084 scopus 로고
    • Phase I clinical trial of weekly and daily treatment with camptothecin sodium (NSC-100880)
    • MUGGIA, F. M., P. J. CREAVEN, H. H. HANSEN, M. H. COHEN & O. S. SELAWRY. 1972. Phase I clinical trial of weekly and daily treatment with camptothecin sodium (NSC-100880). Cancer Chemother. Rep. 56: 515-521.
    • (1972) Cancer Chemother. Rep. , vol.56 , pp. 515-521
    • Muggia, F.M.1    Creaven, P.J.2    Hansen, H.H.3    Cohen, M.H.4    Selawry, O.S.5
  • 3
    • 0015291595 scopus 로고
    • Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer
    • MOERTEL, C. G., A. J. SCHUTT, R. J. REITEMEIER & R. G. HAHN. 1972. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 56: 95-101.
    • (1972) Cancer Chemother. Rep. , vol.56 , pp. 95-101
    • Moertel, C.G.1    Schutt, A.J.2    Reitemeier, R.J.3    Hahn, R.G.4
  • 5
    • 0030054309 scopus 로고    scopus 로고
    • Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
    • MCGUIRE, W. P., W. J. HOSKINS & M. BRADY, 1996. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New Eng. J. Med. 334(2): 1-6.
    • (1996) New Eng. J. Med. , vol.334 , Issue.2 , pp. 1-6
    • Mcguire, W.P.1    Hoskins, W.J.2    Brady, M.3
  • 8
    • 0001134751 scopus 로고
    • Clinical studies with CPT-11: The Japanese experience
    • A239
    • OGAWA, M. & T. TAGUCHI. 1992. Clinical studies with CPT-11: The Japanese experience. Ann. Oncol. 3 (Suppl. 1): 118 (A239).
    • (1992) Ann. Oncol. , vol.3 , Issue.1 SUPPL. , pp. 118
    • Ogawa, M.1    Taguchi, T.2
  • 12
    • 0028158012 scopus 로고
    • Phase I and pharmacological study of the novel topoisomerase 1 inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxycamptothecin (CPT-11) administered as a ninety minute infusion every 3 weeks
    • ROWINSKY, E., L. B. GROCHOW, D. S. ETTINGER, S. E. SARTORIUS, B. G. LUBEJKO, T. L, CHEN, M. K. ROCK & R. C. DONEHOWER. 1994. Phase I and pharmacological study of the novel topoisomerase 1 inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxycamptothecin (CPT-11) administered as a ninety minute infusion every 3 weeks. Cancer Res. 54(2): 427-36.
    • (1994) Cancer Res. , vol.54 , Issue.2 , pp. 427-436
    • Rowinsky, E.1    Grochow, L.B.2    Ettinger, D.S.3    Sartorius, S.E.4    Lubejko, B.G.5    Chen, T.L.6    Rock, M.K.7    Donehower, R.C.8
  • 14
    • 0002207788 scopus 로고
    • CPT-11 (irinotecan) in refractory squamous cell carcinoma of the cervix
    • KAVANAGH, J. J. 1994. CPT-11 (irinotecan) in refractory squamous cell carcinoma of the cervix. Proc. Am. Assoc. Clin. Res. 35: A1397.
    • (1994) Proc. Am. Assoc. Clin. Res. , vol.35
    • Kavanagh, J.J.1
  • 18
    • 0000785315 scopus 로고
    • A phase I study of CPT-11 and cisplatin (5-day continuous infusion) for advanced non-small cell lung cancer
    • MORI, K., U. SUGA, I. KISIHRO, S. OHTO & K. TOMINAGA. 1994. A phase I study of CPT-11 and cisplatin (5-day continuous infusion) for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13: 335.
    • (1994) Proc. Am. Soc. Clin. Oncol. , vol.13 , pp. 335
    • Mori, K.1    Suga, U.2    Kisihro, I.3    Ohto, S.4    Tominaga, K.5
  • 21
    • 0000339156 scopus 로고
    • Randomized phase II trial of two dose schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma: A North Central Cancer Treatment Group (NCCTG) trial
    • A1053
    • WEITH, J. J., S-H. JUNG, R. F. MARSCHKE, JR., T. R. FITCH & J. R. JETT. 1995. Randomized phase II trial of two dose schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma: A North Central Cancer Treatment Group (NCCTG) trial. Proc. Am. Soc. Clin. Oncol. 14: 348 (A1053).
    • (1995) Proc. Am. Soc. Clin. Oncol. , vol.14 , pp. 348
    • Weith, J.J.1    Jung, S.-H.2    Marschke Jr., R.F.3    Fitch, T.R.4    Jett, J.R.5
  • 24
    • 8944242632 scopus 로고
    • Preliminary results of a phase I study of topolecan plus thoracic radiotherapy for locally advanced non-small cell lung cancer
    • A1132
    • GRAHAM, M. V., M. JAHANZEB, C. DRESLER, J. COOPER, B. EMAMI, J. MORTIMER. 1994. Preliminary results of a phase I study of topolecan plus thoracic radiotherapy for locally advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13: 340 (A1132).
    • (1994) Proc. Am. Soc. Clin. Oncol. , vol.13 , pp. 340
    • Graham, M.V.1    Jahanzeb, M.2    Dresler, C.3    Cooper, J.4    Emami, B.5    Mortimer, J.6
  • 25
    • 0025851286 scopus 로고
    • Phase I clinical study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer
    • NEGORO, S., M. FUKUOKA, N. MASUDA, M. TAKADA, Y. KUSUNOKI, K. MATSUI, N. TAKIFUJI, S. KUDOH, H. NIITANI & T. TAGUCHI. 1991. Phase I clinical study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J. Natl. Cancer Inst. 83: 1164-1169.
    • (1991) J. Natl. Cancer Inst. , vol.83 , pp. 1164-1169
    • Negoro, S.1    Fukuoka, M.2    Masuda, N.3    Takada, M.4    Kusunoki, Y.5    Matsui, K.6    Takifuji, N.7    Kudoh, S.8    Niitani, H.9    Taguchi, T.10
  • 27
    • 0000236853 scopus 로고
    • Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer
    • A1110
    • FUJIWARA, Y., M. YAMAKIDO, M. FUKUOKA, S. KUDOH, K. JURUSE & H. IKEGAMI. 1994. Phase II study of irinotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13: 335 (A1110).
    • (1994) Proc. Am. Soc. Clin. Oncol. , vol.13 , pp. 335
    • Fujiwara, Y.1    Yamakido, M.2    Fukuoka, M.3    Kudoh, S.4    Juruse, K.5    Ikegami, H.6
  • 28
    • 1842266121 scopus 로고
    • Phase I study of irinotecan (CPT-11) and etoposide with G-CSF in advanced lung cancer
    • A331
    • NEGORO, S. 1993. Phase I study of irinotecan (CPT-11) and etoposide with G-CSF in advanced lung cancer. Proc. Am. Soc. Clin. Oncol. 12: 133 (A331).
    • (1993) Proc. Am. Soc. Clin. Oncol. , vol.12 , pp. 133
    • Negoro, S.1
  • 31
    • 0011933177 scopus 로고
    • A Phase I study of the topoisomerase I and II inhibitors Topotecan and etoposide
    • ECKARDT, J. R., H. A. BURRIS, G. A. RODRIGUEZ, et al. 1993. A Phase I study of the topoisomerase I and II inhibitors Topotecan and etoposide. Proc. Am. Soc. Clin. Oncol. 11: 138.
    • (1993) Proc. Am. Soc. Clin. Oncol. , vol.11 , pp. 138
    • Eckardt, J.R.1    Burris, H.A.2    Rodriguez, G.A.3
  • 32
    • 0000943872 scopus 로고
    • Phase II study of topotecan in extensive stage small cell lung cancer
    • A1093
    • SCHILLER, J., K. KIM & D. JOHNSON for the EASTERN COOPERATIVE ONCOLOGY GROUP. 1994. Phase II study of topotecan in extensive stage small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12: 330 (A1093).
    • (1994) Proc. Am. Soc. Clin. Oncol. , vol.12 , pp. 330
    • Schiller, J.1    Kim, K.2    Johnson, D.3
  • 37
    • 84889119509 scopus 로고
    • Evaluation of topotecan in resistant and relapsing multiple myeloma: A Southwest Oncology Group study
    • A726
    • KRAUT, E., K. CROWLEY, J. WADE, L. LAUFMAN, G. WEISS, S. TAYLOR & S. SALMON. 1995. Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. Blood 86 (10, Suppl. 1): 185a (A726).
    • (1995) Blood , vol.86 , Issue.10 SUPPL. 1
    • Kraut, E.1    Crowley, K.2    Wade, J.3    Laufman, L.4    Weiss, G.5    Taylor, S.6    Salmon, S.7
  • 38
    • 34447493869 scopus 로고
    • Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia
    • A1335
    • BERAN, M., S. O'BRIEN, S. ARBUCK, S. PIERCE, M. KEATING & H. KANTARJIAN. 1995. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 86 (10, Suppl. 1): 337a (A1335).
    • (1995) Blood , vol.86 , Issue.10 SUPPL. 1
    • Beran, M.1    O'Brien, S.2    Arbuck, S.3    Pierce, S.4    Keating, M.5    Kantarjian, H.6
  • 39
    • 0025153516 scopus 로고
    • Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines
    • OGURO, M., Y. SEKI, K. OKADA & T. ANDOH. 1990. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed. & Pharmacother. 44: 209-216.
    • (1990) Biomed. & Pharmacother. , vol.44 , pp. 209-216
    • Oguro, M.1    Seki, Y.2    Okada, K.3    Andoh, T.4
  • 41
    • 0028292475 scopus 로고
    • Pharmacokinetics of the in vivo and in vivo conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice
    • HINZ, H. R., N. J. HARRIS, E. A. NATELSON & B. C. GIOVANELLA. 1994. Pharmacokinetics of the in vivo and in vivo conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res. 54(11): 3096-3100.
    • (1994) Cancer Res. , vol.54 , Issue.11 , pp. 3096-3100
    • Hinz, H.R.1    Harris, N.J.2    Natelson, E.A.3    Giovanella, B.C.4
  • 42
    • 0028225686 scopus 로고
    • Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan
    • MCCABE, F. L. & R. K. JOHNSON. 1994. Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan. Cancer Invest. 12(3): 308-13.
    • (1994) Cancer Invest. , vol.12 , Issue.3 , pp. 308-313
    • Mccabe, F.L.1    Johnson, R.K.2
  • 43
    • 0027979432 scopus 로고
    • Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors
    • VAN DE ZEE, A. G. J., S. DE JONG, W. N. KEITH, H. HOLLEMA, A. BOONSTRA & E. G. E DE VRIES. 1994. Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res. 54: 149-155.
    • (1994) Cancer Res. , vol.54 , pp. 149-155
    • Van De Zee, A.G.J.1    De Jong, S.2    Keith, W.N.3    Hollema, H.4    Boonstra, A.5    De Vries, E.G.E.6
  • 44
    • 0029029436 scopus 로고
    • topoisomerase I-related parameters and camptothecin activity in colon carcinoma cell lines from the National Cancer Institute anticancer screen
    • GOLDWASSER, F., I. BAE, M. VALENTI, K. TORRES & Y. POMMIER. 1995. topoisomerase I-related parameters and camptothecin activity in colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res. 55: 2116-21.
    • (1995) Cancer Res. , vol.55 , pp. 2116-2121
    • Goldwasser, F.1    Bae, I.2    Valenti, M.3    Torres, K.4    Pommier, Y.5
  • 45
    • 0026625512 scopus 로고
    • The involvement of active DNA synthesis in camptothecin-induced G2 arrest: Altered regulation of p34cdc 2/cyclin B
    • TSAO, Y-P, P. D'ARPA & L. F. LIU. 1992. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: Altered regulation of p34cdc 2/cyclin B. Cancer Res. 52(7): 1823-1829.
    • (1992) Cancer Res. , vol.52 , Issue.7 , pp. 1823-1829
    • Tsao, Y.-P.1    D'Arpa, P.2    Liu, L.F.3
  • 46
    • 0026468470 scopus 로고
    • Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro
    • BURRIS, H. A., III, A-R. HANAUSKE & R. K. JOHNSON et al. 1992. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl. Cancer Inst. 84: 1816-1820.
    • (1992) J. Natl. Cancer Inst. , vol.84 , pp. 1816-1820
    • Burris III, H.A.1    Hanauske, A.-R.2    Johnson, R.K.3
  • 47
    • 0027471350 scopus 로고
    • Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between nontumorigenic and tumorigenic cells in vitro
    • PANTAZIS, P., A. J. KOZIELSKI, J. T. MENDOZA, J. A. EARLY, H. R. HINZ & B. C. GIOVANELLA. 1993. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between nontumorigenic and tumorigenic cells in vitro. Int. J. Cancer 53: 863-871.
    • (1993) Int. J. Cancer , vol.53 , pp. 863-871
    • Pantazis, P.1    Kozielski, A.J.2    Mendoza, J.T.3    Early, J.A.4    Hinz, H.R.5    Giovanella, B.C.6
  • 48
    • 0025084410 scopus 로고
    • Establishment of camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance
    • KANZAWA, F., Y. SUGIMOTO, K. MINATO, K. KASAHARA, M. BUNGO, K. NAKAGAWA, Y. FUJIWARA, L. F. LIU & N. SAIJO. 1990. Establishment of camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance. Cancer Res. 50: 6919-6924.
    • (1990) Cancer Res. , vol.50 , pp. 6919-6924
    • Kanzawa, F.1    Sugimoto, Y.2    Minato, K.3    Kasahara, K.4    Bungo, M.5    Nakagawa, K.6    Fujiwara, Y.7    Liu, L.F.8    Saijo, N.9
  • 49
    • 0026595541 scopus 로고
    • Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin
    • NIIMI, S., K. NAKAGAWA, Y. SUGIMOTO, K. NISHIO, Y. FUJIWARA, S. YOKOYAMA, Y. TERASHIMA & N. SAIJO. 1992. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res. 52: 328-333.
    • (1992) Cancer Res. , vol.52 , pp. 328-333
    • Niimi, S.1    Nakagawa, K.2    Sugimoto, Y.3    Nishio, K.4    Fujiwara, Y.5    Yokoyama, S.6    Terashima, Y.7    Saijo, N.8
  • 50
    • 0025118047 scopus 로고
    • Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells
    • KATZ, E. J., J. S. VICK, K. M. KLING, et al. 1990. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur. J. Cancer 26: 724-727.
    • (1990) Eur. J. Cancer , vol.26 , pp. 724-727
    • Katz, E.J.1    Vick, J.S.2    Kling, K.M.3
  • 51
    • 0026328062 scopus 로고
    • Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan
    • MATTERN, M. R., G. HOFFMAN, F. McCABE, et al. 1991. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan. Cancer Res. 51: 5813-5816.
    • (1991) Cancer Res. , vol.51 , pp. 5813-5816
    • Mattern, M.R.1    Hoffman, G.2    McCabe, F.3
  • 53
    • 0025996996 scopus 로고
    • Intracellular role of SN-38, a metabolite of the camptothecin derivative CPT-11 in the antitumor effect of CPT-11
    • KAWATO, Y., M. AOUNUMA, Y. HIROTO, H. KUGA & K. SATO. 1991. Intracellular role of SN-38, a metabolite of the camptothecin derivative CPT-11 in the antitumor effect of CPT-11. Cancer Res. 51: 4187-4191.
    • (1991) Cancer Res. , vol.51 , pp. 4187-4191
    • Kawato, Y.1    Aounuma, M.2    Hiroto, Y.3    Kuga, H.4    Sato, K.5
  • 56
    • 0026772298 scopus 로고
    • Effect of p-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue
    • HENDRICKS, C. B., E. K. ROWINSKY, L. B. GROCHOW, R. C. DONEHOWER & S. H. KAUFMAN. 1992. Effect of p-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 52: 2268-2278.
    • (1992) Cancer Res. , vol.52 , pp. 2268-2278
    • Hendricks, C.B.1    Rowinsky, E.K.2    Grochow, L.B.3    Donehower, R.C.4    Kaufman, S.H.5
  • 57
    • 0023864510 scopus 로고
    • Antitumor effects of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo
    • TSURUO, T., T. MATSUZAKI, M. MTSUSHITA, H. SAITOS & T. YOKOKURA. 1988. Antitumor effects of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol. 21: 71-74.
    • (1988) Cancer Chemother. Pharmacol. , vol.21 , pp. 71-74
    • Tsuruo, T.1    Matsuzaki, T.2    Mtsushita, M.3    Saitos, H.4    Yokokura, T.5
  • 59
    • 0028022585 scopus 로고
    • Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
    • GUPTA, E., T. M. LESTINGI, R. MICK, J. RAMIREZ, E. E. VOKES & M. J. RATAIN. 1994. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 54: 3723-3725.
    • (1994) Cancer Res. , vol.54 , pp. 3723-3725
    • Gupta, E.1    Lestingi, T.M.2    Mick, R.3    Ramirez, J.4    Vokes, E.E.5    Ratain, M.J.6
  • 60
    • 0011888555 scopus 로고
    • P-glycoprotein mediated excretion of CPT-11 and SN-38: Effect of cyclosporine A
    • A1602
    • GUPTA, E., A. R. SAFA & M. J. RATAIN. 1995. P-glycoprotein mediated excretion of CPT-11 and SN-38: Effect of cyclosporine A. Proc. Am. Soc. Clin. Oncol. 14: 490 (A1602).
    • (1995) Proc. Am. Soc. Clin. Oncol. , vol.14 , pp. 490
    • Gupta, E.1    Safa, A.R.2    Ratain, M.J.3
  • 62
    • 0010287703 scopus 로고    scopus 로고
    • Irinotecan hydrochloride (CPT-11) combined with cisplatin (CDDP) in patients with relapsed or metastatic ovarian cancer
    • #796
    • SUGIYAMA, T., T. NISHIDA, K. USHIJIMA, S. KUMAGAI & M. YSKUSHIJI. 1996. Irinotecan hydrochloride (CPT-11) combined with cisplatin (CDDP) in patients with relapsed or metastatic ovarian cancer. Proc. Am. Soc. Clin. Oncol. 15: 291 (#796).
    • (1996) Proc. Am. Soc. Clin. Oncol. , vol.15 , pp. 291
    • Sugiyama, T.1    Nishida, T.2    Ushijima, K.3    Kumagai, S.4    Yskushiji, M.5
  • 63
    • 0343779479 scopus 로고    scopus 로고
    • Combination of CPT-11 (CPT) with mitomycin-C (MMC) is active for clear cell adenocarcinoma of the ovary (OCA) which is intrinsically CDDP-resistant
    • #761
    • SHIMIZU, Y., S. UMEZAWA & K. HASUMI. 1996. Combination of CPT-11 (CPT) with mitomycin-C (MMC) is active for clear cell adenocarcinoma of the ovary (OCA) which is intrinsically CDDP-resistant. Proc. Am. Soc. Clin. Oncol. 15: 282 (#761).
    • (1996) Proc. Am. Soc. Clin. Oncol. , vol.15 , pp. 282
    • Shimizu, Y.1    Umezawa, S.2    Hasumi, K.3
  • 66
    • 0000391321 scopus 로고    scopus 로고
    • Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial
    • #763
    • GORDON, A., M. BOOKMAN, H. MALMSTROM, G. BOLIS, C. MANGIONI, J. HALL, J. CARTER, I. HUDSON & C. BROOM. 1996. Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial. Proc. Am. Soc. Clin. Oncol. 15: 282 (#763).
    • (1996) Proc. Am. Soc. Clin. Oncol. , vol.15 , pp. 282
    • Gordon, A.1    Bookman, M.2    Malmstrom, H.3    Bolis, G.4    Mangioni, C.5    Hall, J.6    Carter, J.7    Hudson, I.8    Broom, C.9
  • 68
    • 4243843510 scopus 로고    scopus 로고
    • The effect of Topotecan in platinum refractory ovarian cancer
    • #829
    • MALSTROM, H., B. SORBE & E. E. SIMONSEN. 1996. The effect of Topotecan in platinum refractory ovarian cancer. Proc. Am. Soc. Clin. Oncol. 15: 229 (#829).
    • (1996) Proc. Am. Soc. Clin. Oncol. , vol.15 , pp. 229
    • Malstrom, H.1    Sorbe, B.2    Simonsen, E.E.3
  • 70
    • 0000198099 scopus 로고    scopus 로고
    • A phase I-II study of weekly irinotecan (CPT-11) and simultaneous thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (NSCLC)
    • #1102
    • KUDOH, S., N. KURIHARA, K. OKISHIO, K. HIRATA, J. YOSHIKAWA, N. MASUDA, M. TAKADA, K. TAKEDA, S. NEGORO & M. FUKUOKA. 1996. A phase I-II study of weekly irinotecan (CPT-11) and simultaneous thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 15: 372 (#1102).
    • (1996) Proc. Am. Soc. Clin. Oncol. , vol.15 , pp. 372
    • Kudoh, S.1    Kurihara, N.2    Okishio, K.3    Hirata, K.4    Yoshikawa, J.5    Masuda, N.6    Takada, M.7    Takeda, K.8    Negoro, S.9    Fukuoka, M.10

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.